Neuroinflammation is an important pathogenic mechanism in amyotrophic lateral sclerosis (ALS), with regulatory T cells (Tregs) mediating a slower rate of disease progression. Dimethyl fumarate, used in the treatment of relapsing-remitting multiple sclerosis, enhances the anti-inflammatory immune response by suppressing pro-inflammatory T cells and increasing Treg levels. The aim of this study was to assess the efficacy and safety of dimethyl fumarate in sporadic ALS.
Click here for more information on this study
